New hope against Drug-Resistant lung infection?

NCT ID NCT07615309

ENROLLING_BY_INVITATION Disease control Sponsor: Beijing Chest Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the antibiotic omadacycline can help people with a hard-to-treat lung infection caused by Mycobacterium abscessus. Researchers will review medical records of 200 patients to see how many get better or are cured. The goal is to find out which patients benefit most from this drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omadacycline
What this could lead to: If successful, this could provide a new treatment option for a lung infection that is often resistant to many antibiotics.
What could go wrong: This is a retrospective study, not a controlled trial, so results may be less reliable. The infection is notoriously difficult to treat, and omadacycline may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycobacterial infectious disease Mycobacterium Infections, Nontuberculous pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOBACTERIUM ABSCESSUS INFECTION NTM LUNG INFECTION DUE TO MAC

Contacts and locations

Locations

Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis&Thoracic Tumor Research Institute, Beijing, BEIJING 101149

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.